Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease.

ABSTRACT:

Background

Emerging evidence supports the diagnostic and prognostic utility of plasma biomarkers in Alzheimer's disease (AD), particularly in early disease stages. We sought to extend these findings by evaluating the prognostic value of plasma biomarkers in a clinical trial of mild-to-moderate AD.

Methods

Post-hoc analyses investigated whether baseline concentrations of plasma biomarkers (Aβ42/Aβ40, T-tau, P-tau181, NfL, and GFAP) predicted change in ADAS-Cog11, CDR-SB, and volumetric MRI among participants in T2 Protect AD, a negative 48-week, phase-2, placebo-controlled trial of troriluzole in mild-to-moderate AD. All trial participants met diagnostic criteria for probable AD. Baseline concentrations of, and 48-week changes in, plasma biomarkers were assessed for associati

SUBMITTER: Qiu Y 

PROVIDER: S-EPMC12046789 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature